Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: Efficacy, tolerance and response related factors

Hepato-Gastroenterology

Volumn 45, Issue 23, 1998, Pages 1695-1701

  Del Pozo, M A ^f   Arias, J R ^f   Pinilla, J ^a   Labarga, P ^a   Alcoba, M ^b   Martinez De La Cruz, F J ^d,g   Anton, F ^a   Carro, J A ^b   Perez, M R ^b   Echevarria, S ^c   Garrote, E ^f   Moreno Otero, R ^e  

^a Servicio de Medicina Interna   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d Medical Department   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CD4+ lymphocytes; Hepatitis C virus; HIV infection; Interferon alpha 2b; Multicentre trial; Zidovudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CD4 ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; ZIDOVUDINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANOREXIA; ANXIETY; ARTICLE; BLOOD TOXICITY; CHILL; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; CONFUSION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GINGIVA BLEEDING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LEUKOCYTE COUNT; LIBIDO; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; PROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 7844252589     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lindsay KL: Management of Chronic Hepatitis in Special Populations. Amer J Med 1994; 96 (Suppl 1A): S57-S60.
2. Esteban R: Epidemology of hepatitis C virus infection. J Hepatol 1993; 17 (Suppl 3): S67-S71.
3. Weiss RA: How does HIV cause AIDS. Science 1993; 260: 1273-1278.
4. Pawlotsky JM, Ben-Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Throaval F, Deforges L, Duvousch, Zafrani ES, Duval J, Dhumeaux D: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19 (4): 841-848.
5. Cuthbert JA: Hepatitis C: Progress and Problems. Clin Microbiol Rev 1994; 7-4; 505-532.
6. Fischl MA: Treatment of HIV infection. In: Sande MA, Volberding FA, eds. The Medical Management of AIDS. 3rd ed. WB Saunders Company. Philadelphia 1992; 97-110.
7. Alter MJ, Margolis HS, Krawczynski K, Judosn FN, Mares A, Alexander WJ, Hu PY, Muller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.
8. Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Schivazappa L, Ruol A: Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: Evidence of progression to liver cirrhosis. Gut 1982; 23: 270-275.
9. Eyster ME, Diamondstone LS, Lie JM, Ehmann WC, Quan S, Goedert JJ: Natural History of Hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. J Aquir Immune Defic Syndr 1993; 6: 602-610.
10. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic hepatitis non-A, non-B with recombinant human Interferon alpha: A preliminary report. N Engl J Med 1986; 315:1575-1578.
11. Davis GL, Balart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A and The Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant Interferon alpha: A multicentric, randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
12. Di Bisceglie AM, Martin P, Kassianides Ch, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant Interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
13. Marcellin P, Boyer N, Colin JF, Martinot-Pignoux M, Lefort V, Matheron S, Erlinger S, Benhamou JP: Recombinant alpha interferon for chronic hepatitis B in anti-HIV patients receiving zidovudine. Gut 1993; 34 (Suppl 1): S106.
14. Perrillo RP, Regenstein FG, Peters MG, De Schryver-Kecskemeti K, Bodicky CJ, Campbell SS, Kuhns MC: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: A randomized, controlled trial. Ann Intern Med 1988; 109: 95-100.
15. Visco G, Alba L, Grisetti S, Guarascio P, Narciso P, Settle P, Struglia C, Tossini G, Tozzi V: Zidovudine plus interferon alpha 2-b treatment in patients with HIV and chronic active viral hepatitis. Gut 1993 ; 34 (Suppl 1): S107-S108.
16. Knodell RG, Ishak KG, Black WC, Chan TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 ; 1 :431-435.
17. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, Martin-Vega C, Resell M, Aleende H, Vidai X, Gonzalez A, Hernandez JM, Esteban R, Guardia J: High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443-449.
18. Soriano V, Nedjar S, Garcia-Samaniego J, Bravo R, Castro A, Gonzalez J, Martinez-Odriozola P, Pedreira J, del Romero J, Suarez D, Llibre JM, Gonzalez-Lahoz and the Hepatitis-HIV Spanish study group: High rate of co-infection with different Hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. J Hepatol 1995; 22: 598-599.
19. Volderding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth KD and AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases: Zidovudine in asymptomatic human immunodeficiency virus infections: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic milimeter. N Engl J Med 1990; 322: 941-949.
20. Janssen HLA, Berk L, Heijtink RA, Fiebo JW, Ten K, Schalm W: Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial. Hepatology 1993; 17: 838-838.
21. Camps J, Garcia-Granero M, Riezu-Boj JI, Esther L, de Alava E, Civeira MP, Castilla A, Prieto J: Prediction of sustained remission of chronic hepatitis C after 12-month course of alpha interferon. J Hepatol 1994; 21: 4-11.
22. Davis GL: Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
23. Center for Disease Control (CDC): 1993 revised CDC-HIV classification system and expanded AIDS surveillance definition for adolescents and adults. MMWR 1992; 41: 1-17.
24. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4(2): 234-243.
25. Ernstoff MS, Kirkwood JM: Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2b. Am J Med 1984; 76: 593-596.